-
1
-
-
84953238452
-
Towards new avenues in the management of lupus glomerulonephritis
-
Apr
-
[1] Mok, C.C., Towards new avenues in the management of lupus glomerulonephritis. Nat. Rev. Rheumatol. 12:4 (2016 Apr), 221–234, 10.1038/nrrheum.2015.
-
(2016)
Nat. Rev. Rheumatol.
, vol.12
, Issue.4
, pp. 221-234
-
-
Mok, C.C.1
-
2
-
-
0034645414
-
Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995
-
[2] Ward, M.M., Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995. Arch. Intern Med. 160:20 (2000), 3136–3140.
-
(2000)
Arch. Intern Med.
, vol.160
, Issue.20
, pp. 3136-3140
-
-
Ward, M.M.1
-
3
-
-
0026077614
-
Control of adrenal androgen secretion
-
[3] Parker, L.N., Control of adrenal androgen secretion. Endocrinol. Metab. Clin. North Am. 20:2 (1991), 401–421.
-
(1991)
Endocrinol. Metab. Clin. North Am.
, vol.20
, Issue.2
, pp. 401-421
-
-
Parker, L.N.1
-
4
-
-
11144329546
-
Adrenal androgens and the immune system
-
[4] Chen, C.C., Parker, C.R., Adrenal androgens and the immune system. Semin. Reprod. Med. 22:4 (2004), 369–377.
-
(2004)
Semin. Reprod. Med.
, vol.22
, Issue.4
, pp. 369-377
-
-
Chen, C.C.1
Parker, C.R.2
-
5
-
-
33646675132
-
The biological actions of dehydroepiandrosterone involves multiple receptors
-
[5] Webb, S.J., Geoghegan, T.E., Prough, R.A., Michael Miller, K.K., The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab. Rev. 38:1–2 (2006), 89–116.
-
(2006)
Drug Metab. Rev.
, vol.38
, Issue.1-2
, pp. 89-116
-
-
Webb, S.J.1
Geoghegan, T.E.2
Prough, R.A.3
Michael Miller, K.K.4
-
6
-
-
0031835941
-
Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus
-
[6] Derksen, R.H., Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus. Semin. Arthritis Rheum. 27:6 (1998), 335–347.
-
(1998)
Semin. Arthritis Rheum.
, vol.27
, Issue.6
, pp. 335-347
-
-
Derksen, R.H.1
-
7
-
-
0036673428
-
Dissecting human adrenal androgen production
-
[7] Rainey, W.E., Carr, B.R., Sasano, H., Suzuki, T., Mason, J.I., Dissecting human adrenal androgen production. Trends Endocrinol. Metab. 13:6 (2002), 234–239.
-
(2002)
Trends Endocrinol. Metab.
, vol.13
, Issue.6
, pp. 234-239
-
-
Rainey, W.E.1
Carr, B.R.2
Sasano, H.3
Suzuki, T.4
Mason, J.I.5
-
8
-
-
84888380305
-
Genome-wide association studies on serum sex steroid levels
-
[8] Vandenput, L., Ohlsson, C., Genome-wide association studies on serum sex steroid levels. Mol. Cell Endocrinol. 382:1 (2014), 758–766.
-
(2014)
Mol. Cell Endocrinol.
, vol.382
, Issue.1
, pp. 758-766
-
-
Vandenput, L.1
Ohlsson, C.2
-
9
-
-
80155149402
-
Dehydroepiandrosterone (DHEA)–a precursor steroid or an active hormone in human physiology
-
quiz 83
-
[9] Traish, A.M., Kang, H.P., Saad, F., Guay, A.T., Dehydroepiandrosterone (DHEA)–a precursor steroid or an active hormone in human physiology. J. Sex. Med. 8:11 (2011), 2960–2982 quiz 83.
-
(2011)
J. Sex. Med.
, vol.8
, Issue.11
, pp. 2960-2982
-
-
Traish, A.M.1
Kang, H.P.2
Saad, F.3
Guay, A.T.4
-
10
-
-
26844434734
-
Direct agonist/antagonist functions of dehydroepiandrosterone
-
[10] Chen, F., Knecht, K., Birzin, E., Fisher, J., Wilkinson, H., Mojena, M., et al. Direct agonist/antagonist functions of dehydroepiandrosterone. Endocrinology 146:11 (2005), 4568–4576.
-
(2005)
Endocrinology
, vol.146
, Issue.11
, pp. 4568-4576
-
-
Chen, F.1
Knecht, K.2
Birzin, E.3
Fisher, J.4
Wilkinson, H.5
Mojena, M.6
-
11
-
-
0036236065
-
Induction of CYP3A expression by dehydroepiandrosterone: involvement of the pregnane X receptor
-
[11] Ripp, S.L., Fitzpatrick, J.L., Peters, J.M., Prough, R.A., Induction of CYP3A expression by dehydroepiandrosterone: involvement of the pregnane X receptor. Drug Metab. Dispos. 30:5 (2002), 570–575.
-
(2002)
Drug Metab. Dispos.
, vol.30
, Issue.5
, pp. 570-575
-
-
Ripp, S.L.1
Fitzpatrick, J.L.2
Peters, J.M.3
Prough, R.A.4
-
12
-
-
27744455328
-
Sex steroid metabolism in human peripheral blood mononuclear cells changes with aging
-
[12] Hammer, F., Drescher, D.G., Schneider, S.B., Quinkler, M., Stewart, P.M., Allolio, B., et al. Sex steroid metabolism in human peripheral blood mononuclear cells changes with aging. J. Clin. Endocrinol. Metab. 90:11 (2005), 6283–6289.
-
(2005)
J. Clin. Endocrinol. Metab.
, vol.90
, Issue.11
, pp. 6283-6289
-
-
Hammer, F.1
Drescher, D.G.2
Schneider, S.B.3
Quinkler, M.4
Stewart, P.M.5
Allolio, B.6
-
13
-
-
0029555344
-
DHEA and peripheral androgen and estrogen formation: intracinology
-
[13] Labrie, F., Bélanger, A., Simard, J., Van Luu-The, Labrie, C., DHEA and peripheral androgen and estrogen formation: intracinology. Ann. N. Y. Acad. Sci. 774 (1995), 16–28.
-
(1995)
Ann. N. Y. Acad. Sci.
, vol.774
, pp. 16-28
-
-
Labrie, F.1
Bélanger, A.2
Simard, J.3
Van Luu-The4
Labrie, C.5
-
14
-
-
84915756757
-
DHEA, DHEAS and PCOS
-
[14] Goodarzi, M.O., Carmina, E., Azziz, R., DHEA, DHEAS and PCOS. J. Steroid Biochem. Mol. Biol. 145 (2015), 213–225.
-
(2015)
J. Steroid Biochem. Mol. Biol.
, vol.145
, pp. 213-225
-
-
Goodarzi, M.O.1
Carmina, E.2
Azziz, R.3
-
15
-
-
0042574010
-
Sex hormones and systemic lupus erythematosus: review and meta-analysis
-
[15] McMurray, R.W., May, W., Sex hormones and systemic lupus erythematosus: review and meta-analysis. Arthritis Rheum. 48:8 (2003), 2100–2110.
-
(2003)
Arthritis Rheum.
, vol.48
, Issue.8
, pp. 2100-2110
-
-
McMurray, R.W.1
May, W.2
-
16
-
-
0023261410
-
Low plasma androgens in women with systemic lupus erythematosus
-
[16] Lahita, R.G., Bradlow, H.L., Ginzler, E., Pang, S., New, M., Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum. 30:3 (1987), 241–248.
-
(1987)
Arthritis Rheum.
, vol.30
, Issue.3
, pp. 241-248
-
-
Lahita, R.G.1
Bradlow, H.L.2
Ginzler, E.3
Pang, S.4
New, M.5
-
17
-
-
0028962459
-
Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE)
-
[17] Suzuki, T., Suzuki, N., Engleman, E.G., Mizushima, Y., Sakane, T., Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 99:2 (1995), 251–255.
-
(1995)
Clin. Exp. Immunol.
, vol.99
, Issue.2
, pp. 251-255
-
-
Suzuki, T.1
Suzuki, N.2
Engleman, E.G.3
Mizushima, Y.4
Sakane, T.5
-
18
-
-
0031081775
-
Dehydroepiandrosterone (DHEA) treatment of depression
-
[18] Wolkowitz, O.M., Reus, V.I., Roberts, E., Manfredi, F., Chan, T., Raum, W.J., et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol. Psychiatry 41:3 (1997), 311–318.
-
(1997)
Biol. Psychiatry
, vol.41
, Issue.3
, pp. 311-318
-
-
Wolkowitz, O.M.1
Reus, V.I.2
Roberts, E.3
Manfredi, F.4
Chan, T.5
Raum, W.J.6
-
19
-
-
73749083096
-
Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA
-
[19] Ritsner, M.S., Strous, R.D., Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA. J. Psychiatr. Res. 44:2 (2010), 75–80.
-
(2010)
J. Psychiatr. Res.
, vol.44
, Issue.2
, pp. 75-80
-
-
Ritsner, M.S.1
Strous, R.D.2
-
20
-
-
33847048555
-
Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial
-
[20] Strous, R.D., Stryjer, R., Maayan, R., Gal, G., Viglin, D., Katz, E., et al. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinology 32:2 (2007), 96–105.
-
(2007)
Psychoneuroendocrinology
, vol.32
, Issue.2
, pp. 96-105
-
-
Strous, R.D.1
Stryjer, R.2
Maayan, R.3
Gal, G.4
Viglin, D.5
Katz, E.6
-
21
-
-
21044436622
-
Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders
-
[21] Dillon, J.S., Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders. Curr. Drug Targets Inflamm. Allergy 4:3 (2005), 377–385.
-
(2005)
Curr. Drug Targets Inflamm. Allergy
, vol.4
, Issue.3
, pp. 377-385
-
-
Dillon, J.S.1
-
22
-
-
9644269013
-
Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus
-
[22] Chang, D.M., Chu, S.J., Chen, H.C., Kuo, S.Y., Lai, J.H., Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus. Ann. Rheum. Dis. 63:12 (2004), 1623–1626.
-
(2004)
Ann. Rheum. Dis.
, vol.63
, Issue.12
, pp. 1623-1626
-
-
Chang, D.M.1
Chu, S.J.2
Chen, H.C.3
Kuo, S.Y.4
Lai, J.H.5
-
23
-
-
0021972642
-
Prevention of autoantibody formation and prolonged survival in New Zealand black/New Zealand white F1 mice fed dehydroisoandrosterone
-
[23] Lucas, J.A., Ahmed, S.A., Casey, M.L., MacDonald, P.C., Prevention of autoantibody formation and prolonged survival in New Zealand black/New Zealand white F1 mice fed dehydroisoandrosterone. J. Clin. Invest 75:6 (1985), 2091–2093.
-
(1985)
J. Clin. Invest
, vol.75
, Issue.6
, pp. 2091-2093
-
-
Lucas, J.A.1
Ahmed, S.A.2
Casey, M.L.3
MacDonald, P.C.4
-
24
-
-
0031452895
-
Administration of dehydroepiandrosterone sulfate retards onset but not progression of autoimmune disease in NZB/W mice
-
[24] Norton, S.D., Harrison, L.L., Yowell, R., Araneo, B.A., Administration of dehydroepiandrosterone sulfate retards onset but not progression of autoimmune disease in NZB/W mice. Autoimmunity 26:3 (1997), 161–171.
-
(1997)
Autoimmunity
, vol.26
, Issue.3
, pp. 161-171
-
-
Norton, S.D.1
Harrison, L.L.2
Yowell, R.3
Araneo, B.A.4
-
25
-
-
0036210456
-
Dehydroepiandrosterone in relation to other adrenal hormones during an acute inflammatory stressful disease state compared with chronic inflammatory disease: role of interleukin-6 and tumour necrosis factor
-
[25] Straub, R.H., Lehle, K., Herfarth, H., Weber, M., Falk, W., Preuner, J., et al. Dehydroepiandrosterone in relation to other adrenal hormones during an acute inflammatory stressful disease state compared with chronic inflammatory disease: role of interleukin-6 and tumour necrosis factor. Eur. J. Endocrinol. 146:3 (2002), 365–374.
-
(2002)
Eur. J. Endocrinol.
, vol.146
, Issue.3
, pp. 365-374
-
-
Straub, R.H.1
Lehle, K.2
Herfarth, H.3
Weber, M.4
Falk, W.5
Preuner, J.6
-
26
-
-
0030457978
-
Serum and urinary interleukin-6 in systemic lupus erythematosus
-
[26] Peterson, E., Robertson, A.D., Emlen, W., Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus 5:6 (1996), 571–575.
-
(1996)
Lupus
, vol.5
, Issue.6
, pp. 571-575
-
-
Peterson, E.1
Robertson, A.D.2
Emlen, W.3
-
27
-
-
0027237857
-
Urinary levels of IL-6 in patients with active lupus nephritis
-
[27] Iwano, M., Dohi, K., Hirata, E., Kurumatani, N., Horii, Y., Shiiki, H., et al. Urinary levels of IL-6 in patients with active lupus nephritis. Clin. Nephrol. 40:1 (1993), 16–21.
-
(1993)
Clin. Nephrol.
, vol.40
, Issue.1
, pp. 16-21
-
-
Iwano, M.1
Dohi, K.2
Hirata, E.3
Kurumatani, N.4
Horii, Y.5
Shiiki, H.6
-
28
-
-
84890508411
-
Plasma IL-6 levels correlate with clinical and ultrasound measures of arthritis in patients with systemic lupus erythematosus
-
[28] Ball, E.M., Gibson, D.S., Bell, A.L., Rooney, M.R., Plasma IL-6 levels correlate with clinical and ultrasound measures of arthritis in patients with systemic lupus erythematosus. Lupus 23:1 (2014), 46–56.
-
(2014)
Lupus
, vol.23
, Issue.1
, pp. 46-56
-
-
Ball, E.M.1
Gibson, D.S.2
Bell, A.L.3
Rooney, M.R.4
-
29
-
-
0037214074
-
Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE
-
[29] Rönnelid, J., Tejde, A., Mathsson, L., Nilsson-Ekdahl, K., Nilsson, B., Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann. Rheum. Dis. 62:1 (2003), 37–42.
-
(2003)
Ann. Rheum. Dis.
, vol.62
, Issue.1
, pp. 37-42
-
-
Rönnelid, J.1
Tejde, A.2
Mathsson, L.3
Nilsson-Ekdahl, K.4
Nilsson, B.5
-
30
-
-
0028081726
-
An open study of dehydroepiandrosterone in systemic lupus erythematosus
-
[30] van Vollenhoven, R.F., Engleman, E.G., McGuire, J.L., An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum. 37:9 (1994), 1305–1310.
-
(1994)
Arthritis Rheum.
, vol.37
, Issue.9
, pp. 1305-1310
-
-
van Vollenhoven, R.F.1
Engleman, E.G.2
McGuire, J.L.3
-
31
-
-
0032918390
-
A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus
-
[31] van Vollenhoven, R.F., Park, J.L., Genovese, M.C., West, J.P., McGuire, J.L., A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus 8:3 (1999), 181–187.
-
(1999)
Lupus
, vol.8
, Issue.3
, pp. 181-187
-
-
van Vollenhoven, R.F.1
Park, J.L.2
Genovese, M.C.3
West, J.P.4
McGuire, J.L.5
-
32
-
-
0036067464
-
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial
-
[32] Petri, M.A., Lahita, R.G., Van Vollenhoven, R.F., Merrill, J.T., Schiff, M., Ginzler, E.M., et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 46:7 (2002), 1820–1829.
-
(2002)
Arthritis Rheum.
, vol.46
, Issue.7
, pp. 1820-1829
-
-
Petri, M.A.1
Lahita, R.G.2
Van Vollenhoven, R.F.3
Merrill, J.T.4
Schiff, M.5
Ginzler, E.M.6
-
33
-
-
0036845197
-
Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial
-
[33] Chang, D.M., Lan, J.L., Lin, H.Y., Luo, S.F., Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46:11 (2002), 2924–2927.
-
(2002)
Arthritis Rheum.
, vol.46
, Issue.11
, pp. 2924-2927
-
-
Chang, D.M.1
Lan, J.L.2
Lin, H.Y.3
Luo, S.F.4
-
34
-
-
8444220100
-
The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus
-
[34] Hartkamp, A., Geenen, R., Godaert, G.L., Bijl, M., Bijlsma, J.W., Derksen, R.H., The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus. Arthritis Rheum. 50:11 (2004), 3591–3595.
-
(2004)
Arthritis Rheum.
, vol.50
, Issue.11
, pp. 3591-3595
-
-
Hartkamp, A.1
Geenen, R.2
Godaert, G.L.3
Bijl, M.4
Bijlsma, J.W.5
Derksen, R.H.6
-
35
-
-
20244364828
-
Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy
-
[35] Mease, P.J., Ginzler, E.M., Gluck, O.S., Schiff, M., Goldman, A., Greenwald, M., et al. Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy. J. Rheumatol. 32:4 (2005), 616–621.
-
(2005)
J. Rheumatol.
, vol.32
, Issue.4
, pp. 616-621
-
-
Mease, P.J.1
Ginzler, E.M.2
Gluck, O.S.3
Schiff, M.4
Goldman, A.5
Greenwald, M.6
-
36
-
-
49049112006
-
Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy
-
[36] Sánchez-Guerrero, J., Fragoso-Loyo, H.E., Neuwelt, C.M., Wallace, D.J., Ginzler, E.M., Sherrer, Y.R., et al. Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. J. Rheumatol. 35:8 (2008), 1567–1575.
-
(2008)
J. Rheumatol.
, vol.35
, Issue.8
, pp. 1567-1575
-
-
Sánchez-Guerrero, J.1
Fragoso-Loyo, H.E.2
Neuwelt, C.M.3
Wallace, D.J.4
Ginzler, E.M.5
Sherrer, Y.R.6
-
37
-
-
30844446256
-
Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus
-
[37] Nordmark, G., Bengtsson, C., Larsson, A., Karlsson, F.A., Sturfelt, G., Rönnblom, L., Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity 38:7 (2005), 531–540.
-
(2005)
Autoimmunity
, vol.38
, Issue.7
, pp. 531-540
-
-
Nordmark, G.1
Bengtsson, C.2
Larsson, A.3
Karlsson, F.A.4
Sturfelt, G.5
Rönnblom, L.6
-
38
-
-
0031007301
-
The reliability of the systemic lupus international collaborating clinics/american College of Rheumatology damage index in patients with systemic lupus erythematosus
-
[38] Gladman, D.D., Urowitz, M.B., Goldsmith, C.H., Fortin, P., Ginzler, E., Gordon, C., et al. The reliability of the systemic lupus international collaborating clinics/american College of Rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum. 40:5 (1997), 809–813.
-
(1997)
Arthritis Rheum.
, vol.40
, Issue.5
, pp. 809-813
-
-
Gladman, D.D.1
Urowitz, M.B.2
Goldsmith, C.H.3
Fortin, P.4
Ginzler, E.5
Gordon, C.6
-
39
-
-
2642522980
-
The discovery of vitamin D: the contribution of Adolf Windaus
-
[39] Wolf, G., The discovery of vitamin D: the contribution of Adolf Windaus. J. Nutr. 134:6 (2004), 1299–1302.
-
(2004)
J. Nutr.
, vol.134
, Issue.6
, pp. 1299-1302
-
-
Wolf, G.1
-
40
-
-
84962119052
-
Vitamin D status and supplementation before and after bariatric surgery: a comprehensive literature review
-
[40] Peterson, L.A., Zeng, X., Caufield-Noll, C.P., Schweitzer, M.A., Magnuson, T.H., Steele, K.E., Vitamin D status and supplementation before and after bariatric surgery: a comprehensive literature review. Surg. Obes. Relat. Dis. 12:3 (2016), 693–702.
-
(2016)
Surg. Obes. Relat. Dis.
, vol.12
, Issue.3
, pp. 693-702
-
-
Peterson, L.A.1
Zeng, X.2
Caufield-Noll, C.P.3
Schweitzer, M.A.4
Magnuson, T.H.5
Steele, K.E.6
-
41
-
-
34447514029
-
Vitamin D deficiency
-
[41] Holick, M.F., Vitamin D deficiency. N. Engl. J. Med. 357:3 (2007), 266–281.
-
(2007)
N. Engl. J. Med.
, vol.357
, Issue.3
, pp. 266-281
-
-
Holick, M.F.1
-
42
-
-
16244418604
-
Overview of general physiologic features and functions of vitamin D
-
[42] DeLuca, H.F., Overview of general physiologic features and functions of vitamin D. Am. J. Clin. Nutr. 80:6 Suppl (2004), 1689S–1696S.
-
(2004)
Am. J. Clin. Nutr.
, vol.80
, Issue.6
, pp. 1689S-1696S
-
-
DeLuca, H.F.1
-
43
-
-
84949543188
-
Immune response modulation by vitamin D: role in systemic lupus erythematosus
-
[43] Iruretagoyena, M., Hirigoyen, D., Naves, R., Burgos, P.I., Immune response modulation by vitamin D: role in systemic lupus erythematosus. Front. Immunol., 6, 2015, 513.
-
(2015)
Front. Immunol.
, vol.6
, pp. 513
-
-
Iruretagoyena, M.1
Hirigoyen, D.2
Naves, R.3
Burgos, P.I.4
-
44
-
-
78650886291
-
The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know
-
[44] Ross, A.C., Manson, J.E., Abrams, S.A., Aloia, J.F., Brannon, P.M., Clinton, S.K., et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab. 96:1 (2011), 53–58.
-
(2011)
J. Clin. Endocrinol. Metab.
, vol.96
, Issue.1
, pp. 53-58
-
-
Ross, A.C.1
Manson, J.E.2
Abrams, S.A.3
Aloia, J.F.4
Brannon, P.M.5
Clinton, S.K.6
-
45
-
-
77956182419
-
Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice
-
[45] Souberbielle, J.C., Body, J.J., Lappe, J.M., Plebani, M., Shoenfeld, Y., Wang, T.J., et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun. Rev. 9:11 (2010), 709–715.
-
(2010)
Autoimmun. Rev.
, vol.9
, Issue.11
, pp. 709-715
-
-
Souberbielle, J.C.1
Body, J.J.2
Lappe, J.M.3
Plebani, M.4
Shoenfeld, Y.5
Wang, T.J.6
-
46
-
-
27644454006
-
Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers
-
[46] Holick, M.F., Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers. South Med. J. 98:10 (2005), 1024–1027.
-
(2005)
South Med. J.
, vol.98
, Issue.10
, pp. 1024-1027
-
-
Holick, M.F.1
-
47
-
-
77952314178
-
Vitamin D and multiple sclerosis
-
[47] Ascherio, A., Munger, K.L., Simon, K.C., Vitamin D and multiple sclerosis. Lancet Neurol. 9:6 (2010), 599–612.
-
(2010)
Lancet Neurol.
, vol.9
, Issue.6
, pp. 599-612
-
-
Ascherio, A.1
Munger, K.L.2
Simon, K.C.3
-
48
-
-
34547421856
-
Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis
-
[48] Patel, S., Farragher, T., Berry, J., Bunn, D., Silman, A., Symmons, D., Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum. 56:7 (2007), 2143–2149.
-
(2007)
Arthritis Rheum.
, vol.56
, Issue.7
, pp. 2143-2149
-
-
Patel, S.1
Farragher, T.2
Berry, J.3
Bunn, D.4
Silman, A.5
Symmons, D.6
-
49
-
-
0028980323
-
Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus
-
[49] Müller, K., Kriegbaum, N.J., Baslund, B., Sørensen, O.H., Thymann, M., Bentzen, K., Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin. Rheumatol. 14:4 (1995), 397–400.
-
(1995)
Clin. Rheumatol.
, vol.14
, Issue.4
, pp. 397-400
-
-
Müller, K.1
Kriegbaum, N.J.2
Baslund, B.3
Sørensen, O.H.4
Thymann, M.5
Bentzen, K.6
-
50
-
-
80051475298
-
Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus
-
[50] Ritterhouse, L.L., Crowe, S.R., Niewold, T.B., Kamen, D.L., Macwana, S.R., Roberts, V.C., et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 70:9 (2011), 1569–1574.
-
(2011)
Ann. Rheum. Dis.
, vol.70
, Issue.9
, pp. 1569-1574
-
-
Ritterhouse, L.L.1
Crowe, S.R.2
Niewold, T.B.3
Kamen, D.L.4
Macwana, S.R.5
Roberts, V.C.6
-
51
-
-
67651085514
-
Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus
-
[51] Wright, T.B., Shults, J., Leonard, M.B., Zemel, B.S., Burnham, J.M., Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus. J. Pediatr. 155:2 (2009), 260–265.
-
(2009)
J. Pediatr.
, vol.155
, Issue.2
, pp. 260-265
-
-
Wright, T.B.1
Shults, J.2
Leonard, M.B.3
Zemel, B.S.4
Burnham, J.M.5
-
52
-
-
31144446291
-
Vitamin D deficiency in systemic lupus erythematosus
-
[52] Kamen, D.L., Cooper, G.S., Bouali, H., Shaftman, S.R., Hollis, B.W., Gilkeson, G.S., Vitamin D deficiency in systemic lupus erythematosus. Autoimmun. Rev. 5:2 (2006), 114–117.
-
(2006)
Autoimmun. Rev.
, vol.5
, Issue.2
, pp. 114-117
-
-
Kamen, D.L.1
Cooper, G.S.2
Bouali, H.3
Shaftman, S.R.4
Hollis, B.W.5
Gilkeson, G.S.6
-
53
-
-
0034759540
-
Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia
-
[53] Huisman, A.M., White, K.P., Algra, A., Harth, M., Vieth, R., Jacobs, J.W., et al. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J. Rheumatol. 28:11 (2001), 2535–2539.
-
(2001)
J. Rheumatol.
, vol.28
, Issue.11
, pp. 2535-2539
-
-
Huisman, A.M.1
White, K.P.2
Algra, A.3
Harth, M.4
Vieth, R.5
Jacobs, J.W.6
-
54
-
-
33750499270
-
Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
-
[54] Ruiz-Irastorza, G., Egurbide, M.V., Pijoan, J.I., Garmendia, M., Villar, I., Martinez-Berriotxoa, A., et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15:9 (2006), 577–583.
-
(2006)
Lupus
, vol.15
, Issue.9
, pp. 577-583
-
-
Ruiz-Irastorza, G.1
Egurbide, M.V.2
Pijoan, J.I.3
Garmendia, M.4
Villar, I.5
Martinez-Berriotxoa, A.6
-
55
-
-
84877268917
-
Vitamin D and systemic lupus erythematosus: an update
-
[55] Mok, C.C., Vitamin D and systemic lupus erythematosus: an update. Expert Rev. Clin. Immunol. 9:5 (2013), 453–463.
-
(2013)
Expert Rev. Clin. Immunol.
, vol.9
, Issue.5
, pp. 453-463
-
-
Mok, C.C.1
-
56
-
-
84889813182
-
Vitamin D-binding protein and vitamin D status of black Americans and white Americans
-
[56] Powe, C.E., Evans, M.K., Wenger, J., Zonderman, A.B., Berg, A.H., Nalls, M., et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N. Engl. J. Med. 369:21 (2013), 1991–2000.
-
(2013)
N. Engl. J. Med.
, vol.369
, Issue.21
, pp. 1991-2000
-
-
Powe, C.E.1
Evans, M.K.2
Wenger, J.3
Zonderman, A.B.4
Berg, A.H.5
Nalls, M.6
-
57
-
-
84870540921
-
Dietary intake of vitamin D during adolescence and risk of adult-onset systemic lupus erythematosus and rheumatoid arthritis
-
[57] Hiraki, L.T., Munger, K.L., Costenbader, K.H., Karlson, E.W., Dietary intake of vitamin D during adolescence and risk of adult-onset systemic lupus erythematosus and rheumatoid arthritis. Arthritis Care Res. Hob. 64:12 (2012), 1829–1836.
-
(2012)
Arthritis Care Res. Hob.
, vol.64
, Issue.12
, pp. 1829-1836
-
-
Hiraki, L.T.1
Munger, K.L.2
Costenbader, K.H.3
Karlson, E.W.4
-
58
-
-
34548637038
-
Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation
-
[58] Chen, S., Sims, G.P., Chen, X.X., Gu, Y.Y., Lipsky, P.E., Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 179:3 (2007), 1634–1647.
-
(2007)
J. Immunol.
, vol.179
, Issue.3
, pp. 1634-1647
-
-
Chen, S.1
Sims, G.P.2
Chen, X.X.3
Gu, Y.Y.4
Lipsky, P.E.5
-
59
-
-
84856469462
-
Vitamin D and the immune system
-
[59] Aranow, C., Vitamin D and the immune system. J. Investig. Med. 59:6 (2011), 881–886.
-
(2011)
J. Investig. Med.
, vol.59
, Issue.6
, pp. 881-886
-
-
Aranow, C.1
-
60
-
-
84880334803
-
Vitamin D deficiency impacts on expression of toll-like receptor-2 and cytokine profile: a pilot study
-
[60] Ojaimi, S., Skinner, N.A., Strauss, B.J., Sundararajan, V., Woolley, I., Visvanathan, K., Vitamin D deficiency impacts on expression of toll-like receptor-2 and cytokine profile: a pilot study. J. Transl. Med., 11, 2013, 176.
-
(2013)
J. Transl. Med.
, vol.11
, pp. 176
-
-
Ojaimi, S.1
Skinner, N.A.2
Strauss, B.J.3
Sundararajan, V.4
Woolley, I.5
Visvanathan, K.6
-
61
-
-
54049135639
-
Myeloid dendritic cells display downregulation of C-type lectin receptors and aberrant lectin uptake in systemic lupus erythematosus
-
[61] Monrad, S.U., Rea, K., Thacker, S., Kaplan, M.J., Myeloid dendritic cells display downregulation of C-type lectin receptors and aberrant lectin uptake in systemic lupus erythematosus. Arthritis Res. Ther., 10(5), 2008, R114.
-
(2008)
Arthritis Res. Ther.
, vol.10
, Issue.5
, pp. R114
-
-
Monrad, S.U.1
Rea, K.2
Thacker, S.3
Kaplan, M.J.4
-
62
-
-
77949538186
-
The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus
-
[62] Ben-Zvi, I., Aranow, C., Mackay, M., Stanevsky, A., Kamen, D.L., Marinescu, L.M., et al. The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. PLoS One, 5(2), 2010, e9193.
-
(2010)
PLoS One
, vol.5
, Issue.2
, pp. e9193
-
-
Ben-Zvi, I.1
Aranow, C.2
Mackay, M.3
Stanevsky, A.4
Kamen, D.L.5
Marinescu, L.M.6
-
63
-
-
84933037300
-
Randomized, double-blind, placebo-controlled trial of the effect of vitamin D3 on the interferon signature in patients with systemic lupus erythematosus
-
[63] Aranow, C., Kamen, D.L., Dall'Era, M., Massarotti, E.M., Mackay, M.C., Koumpouras, F., et al. Randomized, double-blind, placebo-controlled trial of the effect of vitamin D3 on the interferon signature in patients with systemic lupus erythematosus. Arthritis Rheumatol. 67:7 (2015), 1848–1857.
-
(2015)
Arthritis Rheumatol.
, vol.67
, Issue.7
, pp. 1848-1857
-
-
Aranow, C.1
Kamen, D.L.2
Dall'Era, M.3
Massarotti, E.M.4
Mackay, M.C.5
Koumpouras, F.6
-
64
-
-
60349115516
-
Vitamin D deficiency in patients with active systemic lupus erythematosus
-
[64] Borba, V.Z., Vieira, J.G., Kasamatsu, T., Radominski, S.C., Sato, E.I., Lazaretti-Castro, M., Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos. Int. 20:3 (2009), 427–433.
-
(2009)
Osteoporos. Int.
, vol.20
, Issue.3
, pp. 427-433
-
-
Borba, V.Z.1
Vieira, J.G.2
Kasamatsu, T.3
Radominski, S.C.4
Sato, E.I.5
Lazaretti-Castro, M.6
-
65
-
-
77953716994
-
Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?
-
[65] Amital, H., Szekanecz, Z., Szücs, G., Dankó, K., Nagy, E., Csépány, T., et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?. Ann. Rheum. Dis. 69:6 (2010), 1155–1157.
-
(2010)
Ann. Rheum. Dis.
, vol.69
, Issue.6
, pp. 1155-1157
-
-
Amital, H.1
Szekanecz, Z.2
Szücs, G.3
Dankó, K.4
Nagy, E.5
Csépány, T.6
-
66
-
-
84857058008
-
Vitamin D levels: its relationship to bone mineral density response and disease activity in premenopausal Malaysian systemic lupus erythematosus patients on corticosteroids
-
[66] Yeap, S.S., Othman, A.Z., Zain, A.A., Chan, S.P., Vitamin D levels: its relationship to bone mineral density response and disease activity in premenopausal Malaysian systemic lupus erythematosus patients on corticosteroids. Int. J. Rheum. Dis. 15:1 (2012), 17–24.
-
(2012)
Int. J. Rheum. Dis.
, vol.15
, Issue.1
, pp. 17-24
-
-
Yeap, S.S.1
Othman, A.Z.2
Zain, A.A.3
Chan, S.P.4
-
67
-
-
84857543005
-
25-Hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus
-
[67] Reynolds, J.A., Haque, S., Berry, J.L., Pemberton, P., Teh, L.S., Ho, P., et al. 25-Hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus. Rheumatol. Oxf. 51:3 (2012), 544–551.
-
(2012)
Rheumatol. Oxf.
, vol.51
, Issue.3
, pp. 544-551
-
-
Reynolds, J.A.1
Haque, S.2
Berry, J.L.3
Pemberton, P.4
Teh, L.S.5
Ho, P.6
-
68
-
-
84858648308
-
Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis
-
[68] Mok, C.C., Birmingham, D.J., Leung, H.W., Hebert, L.A., Song, H., Rovin, B.H., Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis. Rheumatol. Oxf. 51:4 (2012), 644–652.
-
(2012)
Rheumatol. Oxf.
, vol.51
, Issue.4
, pp. 644-652
-
-
Mok, C.C.1
Birmingham, D.J.2
Leung, H.W.3
Hebert, L.A.4
Song, H.5
Rovin, B.H.6
-
69
-
-
84905046025
-
25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort
-
[69] Lertratanakul, A., Wu, P., Dyer, A., Urowitz, M., Gladman, D., Fortin, P., et al. 25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. Arthritis Care Res. Hob. 66:8 (2014), 1167–1176.
-
(2014)
Arthritis Care Res. Hob.
, vol.66
, Issue.8
, pp. 1167-1176
-
-
Lertratanakul, A.1
Wu, P.2
Dyer, A.3
Urowitz, M.4
Gladman, D.5
Fortin, P.6
-
70
-
-
0035490503
-
Bone density and 25-OH vitamin D serum level in patients with systemic lupus erythematosus
-
[70] Becker, A., Fischer, R., Schneider, M., Bone density and 25-OH vitamin D serum level in patients with systemic lupus erythematosus. Z Rheumatol. 60:5 (2001), 352–358.
-
(2001)
Z Rheumatol.
, vol.60
, Issue.5
, pp. 352-358
-
-
Becker, A.1
Fischer, R.2
Schneider, M.3
-
71
-
-
80053651571
-
Vitamin D deficiency and its association with disease activity in new cases of systemic lupus erythematosus
-
[71] Bonakdar, Z.S., Jahanshahifar, L., Jahanshahifar, F., Gholamrezaei, A., Vitamin D deficiency and its association with disease activity in new cases of systemic lupus erythematosus. Lupus 20:11 (2011), 1155–1160.
-
(2011)
Lupus
, vol.20
, Issue.11
, pp. 1155-1160
-
-
Bonakdar, Z.S.1
Jahanshahifar, L.2
Jahanshahifar, F.3
Gholamrezaei, A.4
-
72
-
-
77955293368
-
Changes in vitamin D levels in patients with systemic lupus erythematosus: effects on fatigue, disease activity, and damage
-
[72] Ruiz-Irastorza, G., Gordo, S., Olivares, N., Egurbide, M.V., Aguirre, C., Changes in vitamin D levels in patients with systemic lupus erythematosus: effects on fatigue, disease activity, and damage. Arthritis Care Res. Hob. 62:8 (2010), 1160–1165.
-
(2010)
Arthritis Care Res. Hob.
, vol.62
, Issue.8
, pp. 1160-1165
-
-
Ruiz-Irastorza, G.1
Gordo, S.2
Olivares, N.3
Egurbide, M.V.4
Aguirre, C.5
-
73
-
-
84867448448
-
Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation
-
[73] Terrier, B., Derian, N., Schoindre, Y., Chaara, W., Geri, G., Zahr, N., et al. Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis Res. Ther., 14(5), 2012, R221.
-
(2012)
Arthritis Res. Ther.
, vol.14
, Issue.5
, pp. R221
-
-
Terrier, B.1
Derian, N.2
Schoindre, Y.3
Chaara, W.4
Geri, G.5
Zahr, N.6
-
74
-
-
84879867151
-
Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio
-
[74] Petri, M., Bello, K.J., Fang, H., Magder, L.S., Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheum. 65:7 (2013), 1865–1871.
-
(2013)
Arthritis Rheum.
, vol.65
, Issue.7
, pp. 1865-1871
-
-
Petri, M.1
Bello, K.J.2
Fang, H.3
Magder, L.S.4
-
75
-
-
84874881209
-
The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial
-
[75] Abou-Raya, A., Abou-Raya, S., Helmii, M., The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial. J. Rheumatol. 40:3 (2013), 265–272.
-
(2013)
J. Rheumatol.
, vol.40
, Issue.3
, pp. 265-272
-
-
Abou-Raya, A.1
Abou-Raya, S.2
Helmii, M.3
-
76
-
-
84956646097
-
Vitamin D supplementation in adolescents and young adults with juvenile systemic lupus erythematosus for improvement in disease activity and fatigue scores: a randomized, double-blind, placebo-controlled trial
-
[76] Lima, G.L., Paupitz, J., Aikawa, N.E., Takayama, L., Bonfa, E., Pereira, R.M., Vitamin D supplementation in adolescents and young adults with juvenile systemic lupus erythematosus for improvement in disease activity and fatigue scores: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res. Hob. 68:1 (2016), 91–98.
-
(2016)
Arthritis Care Res. Hob.
, vol.68
, Issue.1
, pp. 91-98
-
-
Lima, G.L.1
Paupitz, J.2
Aikawa, N.E.3
Takayama, L.4
Bonfa, E.5
Pereira, R.M.6
-
77
-
-
84925642865
-
A 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosus
-
[77] Andreoli, L., Dall'Ara, F., Piantoni, S., Zanola, A., Piva, N., Cutolo, M., et al. A 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosus. Lupus 24:4–5 (2015), 499–506.
-
(2015)
Lupus
, vol.24
, Issue.4-5
, pp. 499-506
-
-
Andreoli, L.1
Dall'Ara, F.2
Piantoni, S.3
Zanola, A.4
Piva, N.5
Cutolo, M.6
-
78
-
-
56349169572
-
Prevalence of hypovitaminosis D in cardiovascular diseases (from the national health and nutrition examination survey 2001 to 2004)
-
[78] Kim, D.H., Sabour, S., Sagar, U.N., Adams, S., Whellan, D.J., Prevalence of hypovitaminosis D in cardiovascular diseases (from the national health and nutrition examination survey 2001 to 2004). Am. J. Cardiol. 102:11 (2008), 1540–1544.
-
(2008)
Am. J. Cardiol.
, vol.102
, Issue.11
, pp. 1540-1544
-
-
Kim, D.H.1
Sabour, S.2
Sagar, U.N.3
Adams, S.4
Whellan, D.J.5
-
79
-
-
33644878488
-
Reduced vitamin D in acute stroke
-
[79] Poole, K.E., Loveridge, N., Barker, P.J., Halsall, D.J., Rose, C., Reeve, J., et al. Reduced vitamin D in acute stroke. Stroke 37:1 (2006), 243–245.
-
(2006)
Stroke
, vol.37
, Issue.1
, pp. 243-245
-
-
Poole, K.E.1
Loveridge, N.2
Barker, P.J.3
Halsall, D.J.4
Rose, C.5
Reeve, J.6
-
80
-
-
67349254810
-
25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey
-
[80] Kendrick, J., Targher, G., Smits, G., Chonchol, M., 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis 205:1 (2009), 255–260.
-
(2009)
Atherosclerosis
, vol.205
, Issue.1
, pp. 255-260
-
-
Kendrick, J.1
Targher, G.2
Smits, G.3
Chonchol, M.4
-
81
-
-
84866943488
-
Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients
-
[81] Ravenell, R.L., Kamen, D.L., Spence, J.D., Hollis, B.W., Fleury, T.J., Janech, M.G., et al. Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients. Am. J. Med. Sci. 344:4 (2012), 268–273.
-
(2012)
Am. J. Med. Sci.
, vol.344
, Issue.4
, pp. 268-273
-
-
Ravenell, R.L.1
Kamen, D.L.2
Spence, J.D.3
Hollis, B.W.4
Fleury, T.J.5
Janech, M.G.6
-
82
-
-
69749096135
-
Novel evidence-based systemic lupus erythematosus responder index
-
[82] Furie, R.A., Petri, M.A., Wallace, D.J., Ginzler, E.M., Merrill, J.T., Stohl, W., et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 61:9 (2009), 1143–1151.
-
(2009)
Arthritis Rheum.
, vol.61
, Issue.9
, pp. 1143-1151
-
-
Furie, R.A.1
Petri, M.A.2
Wallace, D.J.3
Ginzler, E.M.4
Merrill, J.T.5
Stohl, W.6
-
83
-
-
0026074414
-
A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus
-
[83] A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N. Engl. J. Med. 324:3 (1991), 150–154.
-
(1991)
N. Engl. J. Med.
, vol.324
, Issue.3
, pp. 150-154
-
-
-
84
-
-
34548190213
-
Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)
-
[84] Alarcón, G.S., McGwin, G., Bertoli, A.M., Fessler, B.J., Calvo-Alén, J., Bastian, H.M., et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann. Rheum. Dis. 66:9 (2007), 1168–1172.
-
(2007)
Ann. Rheum. Dis.
, vol.66
, Issue.9
, pp. 1168-1172
-
-
Alarcón, G.S.1
McGwin, G.2
Bertoli, A.M.3
Fessler, B.J.4
Calvo-Alén, J.5
Bastian, H.M.6
-
85
-
-
84867498972
-
Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect
-
[85] Cairoli, E., Rebella, M., Danese, N., Garra, V., Borba, E.F., Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus 21:11 (2012), 1178–1182.
-
(2012)
Lupus
, vol.21
, Issue.11
, pp. 1178-1182
-
-
Cairoli, E.1
Rebella, M.2
Danese, N.3
Garra, V.4
Borba, E.F.5
-
86
-
-
33750955870
-
Hydroxychloroquine in lupus pregnancy
-
[86] Clowse, M.E., Magder, L., Witter, F., Petri, M., Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 54:11 (2006), 3640–3647.
-
(2006)
Arthritis Rheum.
, vol.54
, Issue.11
, pp. 3640-3647
-
-
Clowse, M.E.1
Magder, L.2
Witter, F.3
Petri, M.4
-
87
-
-
0027931521
-
Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus
-
[87] Williams, H.J., Egger, M.J., Singer, J.Z., Willkens, R.F., Kalunian, K.C., Clegg, D.O., et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J. Rheumatol. 21:8 (1994), 1457–1462.
-
(1994)
J. Rheumatol.
, vol.21
, Issue.8
, pp. 1457-1462
-
-
Williams, H.J.1
Egger, M.J.2
Singer, J.Z.3
Willkens, R.F.4
Kalunian, K.C.5
Clegg, D.O.6
-
88
-
-
0036123462
-
Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies
-
[88] Espinola, R.G., Pierangeli, S.S., Gharavi, A.E., Harris, E.N., Ghara, A.E., Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb. Haemost. 87:3 (2002), 518–522.
-
(2002)
Thromb. Haemost.
, vol.87
, Issue.3
, pp. 518-522
-
-
Espinola, R.G.1
Pierangeli, S.S.2
Gharavi, A.E.3
Harris, E.N.4
Ghara, A.E.5
-
89
-
-
33745849739
-
Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis
-
[89] Kasitanon, N., Fine, D.M., Haas, M., Magder, L.S., Petri, M., Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 15:6 (2006), 366–370.
-
(2006)
Lupus
, vol.15
, Issue.6
, pp. 366-370
-
-
Kasitanon, N.1
Fine, D.M.2
Haas, M.3
Magder, L.S.4
Petri, M.5
-
90
-
-
18644363912
-
Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual
-
[90] Fessler, B.J., Alarcón, G.S., McGwin, G., Roseman, J., Bastian, H.M., Friedman, A.W., et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 52:5 (2005), 1473–1480.
-
(2005)
Arthritis Rheum.
, vol.52
, Issue.5
, pp. 1473-1480
-
-
Fessler, B.J.1
Alarcón, G.S.2
McGwin, G.3
Roseman, J.4
Bastian, H.M.5
Friedman, A.W.6
-
91
-
-
84889574291
-
The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review
-
[91] Sutton, E.J., Davidson, J.E., Bruce, I.N., The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin. Arthritis Rheum. 43:3 (2013), 352–361.
-
(2013)
Semin. Arthritis Rheum.
, vol.43
, Issue.3
, pp. 352-361
-
-
Sutton, E.J.1
Davidson, J.E.2
Bruce, I.N.3
-
92
-
-
81155134221
-
Cutaneous lupus erythematosus: update of therapeutic options part I
-
[92] Kuhn, A., Ruland, V., Bonsmann, G., Cutaneous lupus erythematosus: update of therapeutic options part I. J. Am. Acad. Dermatol 65:6 (2011), e179–e193.
-
(2011)
J. Am. Acad. Dermatol
, vol.65
, Issue.6
, pp. e179-e193
-
-
Kuhn, A.1
Ruland, V.2
Bonsmann, G.3
-
93
-
-
79551544891
-
Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients
-
[93] Petri, M., Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr. Rheumatol. Rep. 13:1 (2011), 77–80.
-
(2011)
Curr. Rheumatol. Rep.
, vol.13
, Issue.1
, pp. 77-80
-
-
Petri, M.1
-
94
-
-
58849159669
-
Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort
-
[94] Kaiser, R., Cleveland, C.M., Criswell, L.A., Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann. Rheum. Dis. 68:2 (2009), 238–241.
-
(2009)
Ann. Rheum. Dis.
, vol.68
, Issue.2
, pp. 238-241
-
-
Kaiser, R.1
Cleveland, C.M.2
Criswell, L.A.3
-
95
-
-
58349097555
-
Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies
-
[95] Tektonidou, M.G., Laskari, K., Panagiotakos, D.B., Moutsopoulos, H.M., Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 61:1 (2009), 29–36.
-
(2009)
Arthritis Rheum.
, vol.61
, Issue.1
, pp. 29-36
-
-
Tektonidou, M.G.1
Laskari, K.2
Panagiotakos, D.B.3
Moutsopoulos, H.M.4
-
96
-
-
0026329304
-
Frequency of lupus flare in pregnancy. The Hopkins lupus pregnancy center experience
-
[96] Petri, M., Howard, D., Repke, J., Frequency of lupus flare in pregnancy. The Hopkins lupus pregnancy center experience. Arthritis Rheum. 34:12 (1991), 1538–1545.
-
(1991)
Arthritis Rheum.
, vol.34
, Issue.12
, pp. 1538-1545
-
-
Petri, M.1
Howard, D.2
Repke, J.3
-
97
-
-
84933670410
-
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study
-
[97] Mekinian, A., Lazzaroni, M.G., Kuzenko, A., Alijotas-Reig, J., Ruffatti, A., Levy, P., et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun. Rev. 14:6 (2015), 498–502.
-
(2015)
Autoimmun. Rev.
, vol.14
, Issue.6
, pp. 498-502
-
-
Mekinian, A.1
Lazzaroni, M.G.2
Kuzenko, A.3
Alijotas-Reig, J.4
Ruffatti, A.5
Levy, P.6
-
98
-
-
84997685666
-
Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications
-
Nov
-
[98] Kerr, G., Aujero, M., Richards, J., Sayles, H., Davis, L., Cannon, G., et al. Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. Arthritis Care Res. (Hoboken) 66:11 (2014 Nov), 1619–1626, 10.1002/acr.22341.
-
(2014)
Arthritis Care Res. (Hoboken)
, vol.66
, Issue.11
, pp. 1619-1626
-
-
Kerr, G.1
Aujero, M.2
Richards, J.3
Sayles, H.4
Davis, L.5
Cannon, G.6
-
99
-
-
84982106637
-
Longitudinal evaluation of lipoprotein variables in systemic lupus erythematosus reveals adverse changes with disease activity and prednisone and more favorable profiles with hydroxychloroquine therapy
-
Apr
-
[99] Durcan, L., Winegar, D.A., Connelly, M.A., Otvos, J.D., Magder, L.S., Petri, M., Longitudinal evaluation of lipoprotein variables in systemic lupus erythematosus reveals adverse changes with disease activity and prednisone and more favorable profiles with hydroxychloroquine therapy. J. Rheumatol. 43:4 (2016 Apr), 745–750, 10.3899/jrheum.150437.
-
(2016)
J. Rheumatol.
, vol.43
, Issue.4
, pp. 745-750
-
-
Durcan, L.1
Winegar, D.A.2
Connelly, M.A.3
Otvos, J.D.4
Magder, L.S.5
Petri, M.6
-
100
-
-
84866103485
-
New insights into mechanisms of therapeutic effects of antimalarial agents in SLE
-
[100] Wallace, D.J., Gudsoorkar, V.S., Weisman, M.H., Venuturupalli, S.R., New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat. Rev. Rheumatol. 8:9 (2012), 522–533.
-
(2012)
Nat. Rev. Rheumatol.
, vol.8
, Issue.9
, pp. 522-533
-
-
Wallace, D.J.1
Gudsoorkar, V.S.2
Weisman, M.H.3
Venuturupalli, S.R.4
-
101
-
-
0036175209
-
The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas–a randomized trial
-
[101] Gerstein, H.C., Thorpe, K.E., Taylor, D.W., Haynes, R.B., The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas–a randomized trial. Diabetes Res. Clin. Pract. 55:3 (2002), 209–219.
-
(2002)
Diabetes Res. Clin. Pract.
, vol.55
, Issue.3
, pp. 209-219
-
-
Gerstein, H.C.1
Thorpe, K.E.2
Taylor, D.W.3
Haynes, R.B.4
-
102
-
-
34547208786
-
Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus
-
[102] James, J.A., Kim-Howard, X.R., Bruner, B.F., Jonsson, M.K., McClain, M.T., Arbuckle, M.R., et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 16:6 (2007), 401–409.
-
(2007)
Lupus
, vol.16
, Issue.6
, pp. 401-409
-
-
James, J.A.1
Kim-Howard, X.R.2
Bruner, B.F.3
Jonsson, M.K.4
McClain, M.T.5
Arbuckle, M.R.6
-
103
-
-
77957278745
-
Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine
-
[103] Izmirly, P.M., Kim, M.Y., Llanos, C., Le, P.U., Guerra, M.M., Askanase, A.D., et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann. Rheum. Dis. 69:10 (2010), 1827–1830.
-
(2010)
Ann. Rheum. Dis.
, vol.69
, Issue.10
, pp. 1827-1830
-
-
Izmirly, P.M.1
Kim, M.Y.2
Llanos, C.3
Le, P.U.4
Guerra, M.M.5
Askanase, A.D.6
-
104
-
-
84863625124
-
Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus
-
[104] Izmirly, P.M., Costedoat-Chalumeau, N., Pisoni, C.N., Khamashta, M.A., Kim, M.Y., Saxena, A., et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 126:1 (2012), 76–82.
-
(2012)
Circulation
, vol.126
, Issue.1
, pp. 76-82
-
-
Izmirly, P.M.1
Costedoat-Chalumeau, N.2
Pisoni, C.N.3
Khamashta, M.A.4
Kim, M.Y.5
Saxena, A.6
-
105
-
-
0031038229
-
Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells
-
[105] van den Borne, B.E., Dijkmans, B.A., de Rooij, H.H., le Cessie, S., Verweij, C.L., Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J. Rheumatol. 24:1 (1997), 55–60.
-
(1997)
J. Rheumatol.
, vol.24
, Issue.1
, pp. 55-60
-
-
van den Borne, B.E.1
Dijkmans, B.A.2
de Rooij, H.H.3
le Cessie, S.4
Verweij, C.L.5
-
106
-
-
0032033594
-
Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis
-
[106] Bondeson, J., Sundler, R., Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis. Gen. Pharmacol. 30:3 (1998), 357–366.
-
(1998)
Gen. Pharmacol.
, vol.30
, Issue.3
, pp. 357-366
-
-
Bondeson, J.1
Sundler, R.2
-
107
-
-
84879317702
-
Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients
-
[107] Silva, J.C., Mariz, H.A., Rocha, L.F., Oliveira, P.S., Dantas, A.T., Duarte, A.L., et al. Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clin. (Sao Paulo) 68:6 (2013), 766–771.
-
(2013)
Clin. (Sao Paulo)
, vol.68
, Issue.6
, pp. 766-771
-
-
Silva, J.C.1
Mariz, H.A.2
Rocha, L.F.3
Oliveira, P.S.4
Dantas, A.T.5
Duarte, A.L.6
-
108
-
-
84862752020
-
Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus
-
[108] Sacre, K., Criswell, L.A., McCune, J.M., Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res. Ther., 14(3), 2012, R155.
-
(2012)
Arthritis Res. Ther.
, vol.14
, Issue.3
, pp. R155
-
-
Sacre, K.1
Criswell, L.A.2
McCune, J.M.3
-
109
-
-
84861835445
-
Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort
-
[109] Willis, R., Seif, A.M., McGwin, G., Martinez-Martinez, L.A., González, E.B., Dang, N., et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 21:8 (2012), 830–835.
-
(2012)
Lupus
, vol.21
, Issue.8
, pp. 830-835
-
-
Willis, R.1
Seif, A.M.2
McGwin, G.3
Martinez-Martinez, L.A.4
González, E.B.5
Dang, N.6
-
110
-
-
0000391671
-
Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells
-
[110] Ziegler, H.K., Unanue, E.R., Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc. Natl. Acad. Sci. U. S. A. 79:1 (1982), 175–178.
-
(1982)
Proc. Natl. Acad. Sci. U. S. A.
, vol.79
, Issue.1
, pp. 175-178
-
-
Ziegler, H.K.1
Unanue, E.R.2
-
111
-
-
84902547534
-
Hydroxychloroquine: a multifaceted treatment in lupus
-
[111] Costedoat-Chalumeau, N., Dunogué, B., Morel, N., Le Guern, V., Guettrot-Imbert, G., Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med. 43:6 Pt 2 (2014), e167–e180.
-
(2014)
Presse Med.
, vol.43
, Issue.6
, pp. e167-e180
-
-
Costedoat-Chalumeau, N.1
Dunogué, B.2
Morel, N.3
Le Guern, V.4
Guettrot-Imbert, G.5
-
112
-
-
33750297108
-
Antimalarial agents: closing the gate on Toll-like receptors?
-
[112] Lafyatis, R., York, M., Marshak-Rothstein, A., Antimalarial agents: closing the gate on Toll-like receptors?. Arthritis Rheum. 54:10 (2006), 3068–3070.
-
(2006)
Arthritis Rheum.
, vol.54
, Issue.10
, pp. 3068-3070
-
-
Lafyatis, R.1
York, M.2
Marshak-Rothstein, A.3
-
113
-
-
84928484966
-
Cutting edge: antimalarial drugs inhibit IFN-β production through blockade of cyclic GMP-AMP synthase-DNA interaction
-
[113] An, J., Woodward, J.J., Sasaki, T., Minie, M., Elkon, K.B., Cutting edge: antimalarial drugs inhibit IFN-β production through blockade of cyclic GMP-AMP synthase-DNA interaction. J. Immunol. 194:9 (2015), 4089–4093.
-
(2015)
J. Immunol.
, vol.194
, Issue.9
, pp. 4089-4093
-
-
An, J.1
Woodward, J.J.2
Sasaki, T.3
Minie, M.4
Elkon, K.B.5
-
114
-
-
0026074414
-
A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group
-
[114] A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N. Engl. J. Med. 324:3 (1991), 150–154.
-
(1991)
N. Engl. J. Med.
, vol.324
, Issue.3
, pp. 150-154
-
-
-
115
-
-
84881360370
-
Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials
-
[115] Petri, M.A., van Vollenhoven, R.F., Buyon, J., Levy, R.A., Navarra, S.V., Cervera, R., et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum. 65:8 (2013), 2143–2153.
-
(2013)
Arthritis Rheum.
, vol.65
, Issue.8
, pp. 2143-2153
-
-
Petri, M.A.1
van Vollenhoven, R.F.2
Buyon, J.3
Levy, R.A.4
Navarra, S.V.5
Cervera, R.6
-
116
-
-
33750302628
-
Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus
-
[116] Costedoat-Chalumeau, N., Amoura, Z., Hulot, J.S., Hammoud, H.A., Aymard, G., Cacoub, P., et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 54:10 (2006), 3284–3290.
-
(2006)
Arthritis Rheum.
, vol.54
, Issue.10
, pp. 3284-3290
-
-
Costedoat-Chalumeau, N.1
Amoura, Z.2
Hulot, J.S.3
Hammoud, H.A.4
Aymard, G.5
Cacoub, P.6
-
117
-
-
84859992864
-
Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study
-
[117] Francès, C., Cosnes, A., Duhaut, P., Zahr, N., Soutou, B., Ingen-Housz-Oro, S., et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch. Dermatol 148:4 (2012), 479–484.
-
(2012)
Arch. Dermatol
, vol.148
, Issue.4
, pp. 479-484
-
-
Francès, C.1
Cosnes, A.2
Duhaut, P.3
Zahr, N.4
Soutou, B.5
Ingen-Housz-Oro, S.6
-
118
-
-
84881322752
-
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)
-
[118] Costedoat-Chalumeau, N., Galicier, L., Aumaitre, O., Frances, C., Le Guern, V., Liote, F., et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann. Rheum. Dis. 72:11 (2013), 1786–1792.
-
(2013)
Ann. Rheum. Dis.
, vol.72
, Issue.11
, pp. 1786-1792
-
-
Costedoat-Chalumeau, N.1
Galicier, L.2
Aumaitre, O.3
Frances, C.4
Le Guern, V.5
Liote, F.6
-
119
-
-
84946606371
-
Hydroxychloroquine blood levels in SLE: clarifying dosing controversies and improving adherence
-
Nov
-
[119] Durcan, L., Clarke, W.A., Magder, L.S., Petri, M., Hydroxychloroquine blood levels in SLE: clarifying dosing controversies and improving adherence. J. Rheumatol. 42:11 (2015 Nov), 2092–2097, 10.3899/jrheum.150379.
-
(2015)
J. Rheumatol.
, vol.42
, Issue.11
, pp. 2092-2097
-
-
Durcan, L.1
Clarke, W.A.2
Magder, L.S.3
Petri, M.4
-
120
-
-
0027931521
-
Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus
-
[120] Williams, H.J., Egger, M.J., Singer, J.Z., Willkens, R.F., Kalunian, K.C., Clegg, D.O., et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J. Rheumatol. 21:8 (1994), 1457–1462.
-
(1994)
J. Rheumatol.
, vol.21
, Issue.8
, pp. 1457-1462
-
-
Williams, H.J.1
Egger, M.J.2
Singer, J.Z.3
Willkens, R.F.4
Kalunian, K.C.5
Clegg, D.O.6
-
121
-
-
84881557131
-
Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: a review of published literature and registered clinical trials
-
[121] Gleicher, N., Elkayam, U., Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: a review of published literature and registered clinical trials. Autoimmun. Rev. 12:11 (2013), 1039–1045.
-
(2013)
Autoimmun. Rev.
, vol.12
, Issue.11
, pp. 1039-1045
-
-
Gleicher, N.1
Elkayam, U.2
-
122
-
-
77949879784
-
Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block
-
[122] Clancy, R.M., Alvarez, D., Komissarova, E., Barrat, F.J., Swartz, J., Buyon, J.P., Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block. J. Immunol. 184:4 (2010), 2148–2155.
-
(2010)
J. Immunol.
, vol.184
, Issue.4
, pp. 2148-2155
-
-
Clancy, R.M.1
Alvarez, D.2
Komissarova, E.3
Barrat, F.J.4
Swartz, J.5
Buyon, J.P.6
-
123
-
-
84918584162
-
The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy
-
[123] Melles, R.B., Marmor, M.F., The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 132:12 (2014), 1453–1460.
-
(2014)
JAMA Ophthalmol.
, vol.132
, Issue.12
, pp. 1453-1460
-
-
Melles, R.B.1
Marmor, M.F.2
-
124
-
-
79551548116
-
Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy
-
[124] Marmor, M.F., Kellner, U., Lai, T.Y., Lyons, J.S., Mieler, W.F., Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118:2 (2011), 415–422.
-
(2011)
Ophthalmology
, vol.118
, Issue.2
, pp. 415-422
-
-
Marmor, M.F.1
Kellner, U.2
Lai, T.Y.3
Lyons, J.S.4
Mieler, W.F.5
-
125
-
-
81255146464
-
Mechanisms of B cell autoimmunity in SLE
-
[125] Dörner, T., Giesecke, C., Lipsky, P.E., Mechanisms of B cell autoimmunity in SLE. Arthritis Res. Ther., 13(5), 2011, 243.
-
(2011)
Arthritis Res. Ther.
, vol.13
, Issue.5
, pp. 243
-
-
Dörner, T.1
Giesecke, C.2
Lipsky, P.E.3
-
126
-
-
84883257895
-
Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study
-
[126] Mysler, E.F., Spindler, A.J., Guzman, R., Bijl, M., Jayne, D., Furie, R.A., et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 65:9 (2013), 2368–2379.
-
(2013)
Arthritis Rheum.
, vol.65
, Issue.9
, pp. 2368-2379
-
-
Mysler, E.F.1
Spindler, A.J.2
Guzman, R.3
Bijl, M.4
Jayne, D.5
Furie, R.A.6
-
127
-
-
74849131972
-
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
-
[127] Merrill, J.T., Neuwelt, C.M., Wallace, D.J., Shanahan, J.C., Latinis, K.M., Oates, J.C., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62:1 (2010), 222–233.
-
(2010)
Arthritis Rheum.
, vol.62
, Issue.1
, pp. 222-233
-
-
Merrill, J.T.1
Neuwelt, C.M.2
Wallace, D.J.3
Shanahan, J.C.4
Latinis, K.M.5
Oates, J.C.6
-
128
-
-
84879502096
-
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up
-
[128] Wallace, D.J., Gordon, C., Strand, V., Hobbs, K., Petri, M., Kalunian, K., et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatol. Oxf. 52:7 (2013), 1313–1322.
-
(2013)
Rheumatol. Oxf.
, vol.52
, Issue.7
, pp. 1313-1322
-
-
Wallace, D.J.1
Gordon, C.2
Strand, V.3
Hobbs, K.4
Petri, M.5
Kalunian, K.6
-
129
-
-
82455198794
-
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
-
[129] Furie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D.J., Tegzová, D., et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63:12 (2011), 3918–3930.
-
(2011)
Arthritis Rheum.
, vol.63
, Issue.12
, pp. 3918-3930
-
-
Furie, R.1
Petri, M.2
Zamani, O.3
Cervera, R.4
Wallace, D.J.5
Tegzová, D.6
-
130
-
-
84942111128
-
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study
-
[130] Furie, R.A., Leon, G., Thomas, M., Petri, M.A., Chu, A.D., Hislop, C., et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann. Rheum. Dis. 74:9 (2015), 1667–1675.
-
(2015)
Ann. Rheum. Dis.
, vol.74
, Issue.9
, pp. 1667-1675
-
-
Furie, R.A.1
Leon, G.2
Thomas, M.3
Petri, M.A.4
Chu, A.D.5
Hislop, C.6
-
131
-
-
84954302328
-
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
-
[131] Isenberg, D.A., Petri, M., Kalunian, K., Tanaka, Y., Urowitz, M.B., Hoffman, R.W., et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 75:2 (2016), 323–331.
-
(2016)
Ann. Rheum. Dis.
, vol.75
, Issue.2
, pp. 323-331
-
-
Isenberg, D.A.1
Petri, M.2
Kalunian, K.3
Tanaka, Y.4
Urowitz, M.B.5
Hoffman, R.W.6
-
132
-
-
84945242898
-
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
-
[132] Isenberg, D., Gordon, C., Licu, D., Copt, S., Rossi, C.P., Wofsy, D., Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann. Rheum. Dis. 74:11 (2015), 2006–2015.
-
(2015)
Ann. Rheum. Dis.
, vol.74
, Issue.11
, pp. 2006-2015
-
-
Isenberg, D.1
Gordon, C.2
Licu, D.3
Copt, S.4
Rossi, C.P.5
Wofsy, D.6
-
133
-
-
79952070370
-
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
-
[133] Navarra, S.V., Guzmán, R.M., Gallacher, A.E., Hall, S., Levy, R.A., Jimenez, R.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:9767 (2011), 721–731.
-
(2011)
Lancet
, vol.377
, Issue.9767
, pp. 721-731
-
-
Navarra, S.V.1
Guzmán, R.M.2
Gallacher, A.E.3
Hall, S.4
Levy, R.A.5
Jimenez, R.E.6
-
134
-
-
84862002288
-
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus
-
[134] Stohl, W., Hiepe, F., Latinis, K.M., Thomas, M., Scheinberg, M.A., Clarke, A., et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 64:7 (2012), 2328–2337.
-
(2012)
Arthritis Rheum.
, vol.64
, Issue.7
, pp. 2328-2337
-
-
Stohl, W.1
Hiepe, F.2
Latinis, K.M.3
Thomas, M.4
Scheinberg, M.A.5
Clarke, A.6
-
135
-
-
84863850571
-
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
-
[135] van Vollenhoven, R.F., Petri, M.A., Cervera, R., Roth, D.A., Ji, B.N., Kleoudis, C.S., et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann. Rheum. Dis. 71:8 (2012), 1343–1349.
-
(2012)
Ann. Rheum. Dis.
, vol.71
, Issue.8
, pp. 1343-1349
-
-
van Vollenhoven, R.F.1
Petri, M.A.2
Cervera, R.3
Roth, D.A.4
Ji, B.N.5
Kleoudis, C.S.6
-
136
-
-
84871574493
-
Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE
-
[136] Dooley, M.A., Houssiau, F., Aranow, C., D'Cruz, D.P., Askanase, A., Roth, D.A., et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22:1 (2013), 63–72.
-
(2013)
Lupus
, vol.22
, Issue.1
, pp. 63-72
-
-
Dooley, M.A.1
Houssiau, F.2
Aranow, C.3
D'Cruz, D.P.4
Askanase, A.5
Roth, D.A.6
-
137
-
-
82755160832
-
Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus
-
[137] Illei, G.G., Cervera, R., Burt, R.K., Doria, A., Hiepe, F., Jayne, D., et al. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann. Rheum. Dis. 70:12 (2011), 2071–2074.
-
(2011)
Ann. Rheum. Dis.
, vol.70
, Issue.12
, pp. 2071-2074
-
-
Illei, G.G.1
Cervera, R.2
Burt, R.K.3
Doria, A.4
Hiepe, F.5
Jayne, D.6
-
138
-
-
78649742723
-
Stem cell transplantation: progress in Asia
-
[138] Sun, L., Stem cell transplantation: progress in Asia. Lupus 19:12 (2010), 1468–1473.
-
(2010)
Lupus
, vol.19
, Issue.12
, pp. 1468-1473
-
-
Sun, L.1
-
139
-
-
0027199515
-
Immune ablation with stem-cell rescue: a possible cure for systemic lupus erythematosus?
-
[139] Marmont, A.M., Immune ablation with stem-cell rescue: a possible cure for systemic lupus erythematosus?. Lupus 2:3 (1993), 151–156.
-
(1993)
Lupus
, vol.2
, Issue.3
, pp. 151-156
-
-
Marmont, A.M.1
-
140
-
-
11144357974
-
Autologous stem cell transplantation for systemic lupus erythematosus
-
[140] Jayne, D., Passweg, J., Marmont, A., Farge, D., Zhao, X., Arnold, R., et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 13:3 (2004), 168–176.
-
(2004)
Lupus
, vol.13
, Issue.3
, pp. 168-176
-
-
Jayne, D.1
Passweg, J.2
Marmont, A.3
Farge, D.4
Zhao, X.5
Arnold, R.6
-
141
-
-
0034718372
-
Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study
-
[141] Traynor, A.E., Schroeder, J., Rosa, R.M., Cheng, D., Stefka, J., Mujais, S., et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet 356:9231 (2000), 701–707.
-
(2000)
Lancet
, vol.356
, Issue.9231
, pp. 701-707
-
-
Traynor, A.E.1
Schroeder, J.2
Rosa, R.M.3
Cheng, D.4
Stefka, J.5
Mujais, S.6
-
142
-
-
59449092041
-
Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system
-
[142] Alexander, T., Thiel, A., Rosen, O., Massenkeil, G., Sattler, A., Kohler, S., et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 113:1 (2009), 214–223.
-
(2009)
Blood
, vol.113
, Issue.1
, pp. 214-223
-
-
Alexander, T.1
Thiel, A.2
Rosen, O.3
Massenkeil, G.4
Sattler, A.5
Kohler, S.6
-
143
-
-
76349096767
-
Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus
-
[143] Zhang, L., Bertucci, A.M., Ramsey-Goldman, R., Burt, R.K., Datta, S.K., Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus. J. Immunol. 183:10 (2009), 6346–6358.
-
(2009)
J. Immunol.
, vol.183
, Issue.10
, pp. 6346-6358
-
-
Zhang, L.1
Bertucci, A.M.2
Ramsey-Goldman, R.3
Burt, R.K.4
Datta, S.K.5
-
144
-
-
84904993611
-
A CD8 T cell/indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus
-
[144] Wang, D., Feng, X., Lu, L., Konkel, J.E., Zhang, H., Chen, Z., et al. A CD8 T cell/indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus. Arthritis Rheumatol. 66:8 (2014), 2234–2245.
-
(2014)
Arthritis Rheumatol.
, vol.66
, Issue.8
, pp. 2234-2245
-
-
Wang, D.1
Feng, X.2
Lu, L.3
Konkel, J.E.4
Zhang, H.5
Chen, Z.6
-
145
-
-
4444300345
-
Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus
-
[145] Petri, M.A., Mease, P.J., Merrill, J.T., Lahita, R.G., Iannini, M.J., Yocum, D.E., et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 50:9 (2004), 2858–2868.
-
(2004)
Arthritis Rheum.
, vol.50
, Issue.9
, pp. 2858-2868
-
-
Petri, M.A.1
Mease, P.J.2
Merrill, J.T.3
Lahita, R.G.4
Iannini, M.J.5
Yocum, D.E.6
-
146
-
-
77952793334
-
Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial
-
[146] Hartkamp, A., Geenen, R., Godaert, G.L., Bijl, M., Bijlsma, J.W., Derksen, R.H., Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial. Ann. Rheum. Dis. 69:6 (2010), 1144–1147.
-
(2010)
Ann. Rheum. Dis.
, vol.69
, Issue.6
, pp. 1144-1147
-
-
Hartkamp, A.1
Geenen, R.2
Godaert, G.L.3
Bijl, M.4
Bijlsma, J.W.5
Derksen, R.H.6
-
147
-
-
84925626423
-
Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D
-
[147] Piantoni, S., Andreoli, L., Scarsi, M., Zanola, A., Dall'Ara, F., Pizzorni, C., et al. Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D. Lupus 24:4–5 (2015), 490–498.
-
(2015)
Lupus
, vol.24
, Issue.4-5
, pp. 490-498
-
-
Piantoni, S.1
Andreoli, L.2
Scarsi, M.3
Zanola, A.4
Dall'Ara, F.5
Pizzorni, C.6
-
148
-
-
0034990187
-
Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study
-
[148] Levy, R.A., Vilela, V.S., Cataldo, M.J., Ramos, R.C., Duarte, J.L., Tura, B.R., et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 10:6 (2001), 401–404.
-
(2001)
Lupus
, vol.10
, Issue.6
, pp. 401-404
-
-
Levy, R.A.1
Vilela, V.S.2
Cataldo, M.J.3
Ramos, R.C.4
Duarte, J.L.5
Tura, B.R.6
|